hVIVO CEO Yamin ‘Mo’ Khan presenting in-person at the Jefferies Healthcare Conference

hVIVO plc

hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Yamin ‘Mo’ Khan, Chief Executive Officer, will be presenting in-person at the Jefferies Healthcare Conference in London on 19 November 2024 at 12:00pm GMT. Alongside the presentation, the Company will also be available for one-to-one meetings.

The Jefferies Conference is the largest healthcare-dedicated conference in Europe. The conference hosts over 650 healthcare companies, 3,000 attendees, and nearly 8,000 investor and business-to-business meetings. The conference will feature leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.

hVIVO is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

hVIVO publishes 2024 report and announces Board changes

hVIVO plc announces the release of its 2024 Annual Report and upcoming AGM, along with notable board changes, including the departure of key directors.

hVIVO delivers record 2024 results, revenue up 11.9% and EBITDA up 25.9%

hVIVO plc reports impressive audited results for 2024, showcasing a revenue increase and strong EBITDA growth in the human challenge clinical trial sector.

hVIVO to host Final Results Analyst Briefing on 10 April 2025

hVIVO plc (LON:HVO), a leader in human challenge clinical trials, will announce its 2024 results on April 10, 2025, with an analyst briefing to follow.

hVIVO expands hLAB and biobank service with Cryostore acquisition

hVIVO plc, a leader in human challenge clinical trials, has acquired Cryo-Store Limited to enhance its biobank and laboratory services with advanced storage solutions.

hVIVO signs new £2 million hMPV characterisation study contract

hVIVO plc secures a £2 million contract post-successful hMPV trial, advancing critical human challenge studies for future vaccine development.

hVIVO reports positive results from RSV antiviral human challenge trial with Shionogi

hVIVO plc, a leader in human challenge clinical trials, reports successful Phase 2a results for Shionogi's RSV antiviral, S-337395, showing significant efficacy.

Search

Search